Johnson & Johnson (NYSE:JNJ) Shares Sold by CNB Bank

CNB Bank cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 6.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 7,368 shares of the company’s stock after selling 530 shares during the quarter. CNB Bank’s holdings in Johnson & Johnson were worth $1,066,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Saxon Interests Inc. lifted its stake in Johnson & Johnson by 13.3% during the fourth quarter. Saxon Interests Inc. now owns 7,730 shares of the company’s stock worth $1,118,000 after purchasing an additional 907 shares during the last quarter. Avanza Fonder AB purchased a new stake in Johnson & Johnson during the fourth quarter worth approximately $37,420,000. Tompkins Financial Corp lifted its stake in Johnson & Johnson by 16.1% during the fourth quarter. Tompkins Financial Corp now owns 37,374 shares of the company’s stock worth $5,405,000 after purchasing an additional 5,177 shares during the last quarter. Total Wealth Planning LLC lifted its stake in Johnson & Johnson by 4.6% during the fourth quarter. Total Wealth Planning LLC now owns 2,004 shares of the company’s stock worth $290,000 after purchasing an additional 89 shares during the last quarter. Finally, Hennessy Advisors Inc. lifted its stake in Johnson & Johnson by 2.7% in the fourth quarter. Hennessy Advisors Inc. now owns 55,350 shares of the company’s stock valued at $8,005,000 after buying an additional 1,450 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 0.5 %

Shares of JNJ stock opened at $147.03 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market capitalization of $353.99 billion, a PE ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 0.51. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The business’s fifty day moving average price is $148.51 and its 200 day moving average price is $155.96.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.37%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on JNJ shares. Wolfe Research started coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective for the company. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Bank of America reduced their price objective on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating for the company in a research note on Friday. Citigroup reduced their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.29.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.